Oncology Biomarkers Market Anticipated to Record Steady Gains, Advancing to $33.63 Billion by 2030
Uncover key drivers, emerging technologies, and competitive movements shaping the worker heat stress monitoring wearable market from 2026–2035 with trusted insights from The Business Research Company
What level of CAGR-driven expansion is anticipated in the Oncology Biomarkers Market between 2026 and 2030?
The oncology biomarkers market size has shown substantial growth in recent years. It is anticipated to increase from $17.3 billion in 2025 to $19.73 billion in 2026, registering a compound annual growth rate (CAGR) of 14.1%. This historical growth can be attributed to the broadening of cancer screening programs, advancements in molecular biology research, improved access to biomarker testing platforms, an increase in oncology clinical trials, and greater collaboration among research institutions and hospitals.
The oncology biomarkers market is projected to experience significant expansion over the coming years. Its valuation is anticipated to reach $33.63 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 14.3%. This anticipated growth during the forecast timeframe stems from factors such as the heightened demand for customized oncology treatments, the broader deployment of AI in biomarker identification, increasing capital allocated to cancer genomics research, the greater uptake of liquid biopsy techniques, and a sharpened emphasis on the early identification and surveillance of cancer. Key trends characterizing this period encompass the wider acceptance of precision oncology diagnostics, an uptick in the utilization of genetic and protein biomarkers, the increasing incorporation of bioinformatics into biomarker assessment, an expansion in the creation of companion diagnostics, and an intensified commitment to individualized cancer therapy.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12493&type=smp
What Drivers Are Affecting Demand-Supply Dynamics In The Oncology Biomarkers Market?
The increasing occurrence of cancer is anticipated to drive the expansion of the oncology biomarker market in the future. Cancer is a condition where certain body cells multiply uncontrollably and progressively disseminate throughout the body. Oncological biomarkers offer more detailed information about the specific type of cancer by examining genes, proteins, and other substances present in a person’s system. For instance, in February 2024, according to the World Health Organization, an intergovernmental organization located in Switzerland, projections indicated that by 2050, there would be over 35 million new cancer cases, representing a 77% increase compared to the estimated 20 million cases in 2022. Therefore, the growing incidence of cancer is propelling the growth of the oncology biomarkers market.
What Segments Are Included Within The Oncology Biomarkers Market?
The oncology biomarkers market covered in this report is segmented –
1) By Biomarker Type: Protein Biomarkers, Genetic Biomarkers, Other Biomarker Types
2) By Cancer Type: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Leukemia, Ovarian Cancer, Liver Cancer, Other Cancer Types
3) By Application: Diagnostics, Research And Development, Prognostics, Risk Assessment, Other Applications
4) By End-User: Hospitals, Academic And Cancer Research Institutes, Diagnostic Laboratories
Subsegments:
1) By Protein Biomarkers: Tumor-Specific Antigens, Circulating Tumor Cells (CTCs), Enzymatic Biomarkers
2) By Genetic Biomarkers: DNA Mutations, Gene Expression Profiles, Single Nucleotide Polymorphisms (SNPs)
3) By Other Biomarker Types: Metabolomic Biomarkers, Epigenetic Biomarkers, MicroRNA Biomarkers
What Trends Are Driving The Growth Trajectory Of The Oncology Biomarkers Market?
Leading companies in the oncology diagnostics market are concentrating on developing advanced biomarker-based assays. These are designed to improve the early detection of cancer, monitor minimal residual disease (MRD), and assess how patients respond to various therapies. Minimal residual disease refers to the minute quantity of cancer cells that may persist in the body following treatment, which carries the risk of recurrence if not identified. For instance, in May 2024, Tempus, a US-based artificial intelligence and precision medicine company, introduced its portfolio of MRD tests. This portfolio features the xM test and the xM (NeXT Personal Dx) test, developed by Personalis. The collection includes both tumor-naïve and tumor-informed assays, intended to detect early cancer recurrence and residual disease, as well as to monitor patient reactions to immunotherapy. By utilizing circulating tumor biomarkers, these assays furnish clinicians with sensitive and actionable insights to guide patient management strategies.
Who Are The Prominent Global Companies Shaping The Oncology Biomarkers Market Landscape?
Major companies operating in the oncology biomarkers market are F Hoffmann-La Roche AG, Novartis AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Merck KGaA, Siemens Healthcare GmbH, Becton Dickinson and Company, GE Healthcare Technologies Inc., Eurofins Scientific SE, Agilent Technologies Inc., Hologic Inc., Illumina Inc., bioMerieux SA, Bio-Rad Laboratories Inc., Bruker Corporation, QIAGEN NV, Exact Sciences Corporation, Sysmex Corporation, PerkinElmer Inc., Leica Biosystems, Myriad Genetics Inc., Guardant Health Inc., Enzo Biochem Inc., Biocartis Group NV, Agendia Inc., Epigenomics AG, OncoDNA SA
Access The Complete Report For Deeper Market Insights:
https://www.thebusinessresearchcompany.com/report/oncology-biomarkers-global-market-report
Which Region Is Projected To Lead The Oncology Biomarkers Market During The Forecast Period?
North America was the largest region in the oncology biomarkers market in 2025. The regions covered in the oncology biomarkers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Oncology Biomarkers Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=12493&type=smp
Browse Through More Reports Similar to the Global Oncology Biomarkers Market 2026, By The Business Research Company
Cancer Biomarker Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/cancer-biomarker-global-market-report
Clinical Biomarkers Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/clinical-biomarkers-global-market-report
Clinical Oncology Next Generation Sequencing Global Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
